34.55 -0.23 (-0.66%)
After hours: 5:42PM EDT
|Bid||32.56 x 100|
|Ask||34.99 x 100|
|Day's Range||34.49 - 34.89|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||22.81|
|Dividend & Yield||0.90 (2.63%)|
|1y Target Est||37.37|
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration has accepted a supplemental Biologics License Application for IMFINZI® for the treatment of patients with locally advanced, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.
AstraZeneca today announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for TAGRISSO® for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer .
AstraZeneca and Tesaro stocks were in a slump Tuesday, a day after an institute doubted the cost-effectiveness of their cancer drugs.